CW Advisors LLC Buys Shares of 4,122 Solventum Corporation $SOLV

Key Points

• CW Advisors LLC has acquired a new stake in Solventum Corporation, buying 4,122 shares valued at approximately $312,000 in the 1st quarter.
• Several institutional investors have recently increased their holdings in Solventum, with SouthState Corp raising its position by 31.9%.
• Analysts have mixed ratings on Solventum, with Morgan Stanley upgrading their rating to "overweight" and raising the price target from $80.00 to $103.00.

CW Advisors LLC acquired a new stake in shares of Solventum Corporation (NYSE:SOLV - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 4,122 shares of the company's stock, valued at approximately $312,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new position in shares of Solventum during the 4th quarter worth approximately $378,000. Price T Rowe Associates Inc. MD raised its stake in shares of Solventum by 0.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 200,542 shares of the company's stock worth $13,249,000 after buying an additional 770 shares in the last quarter. Quarry LP purchased a new position in shares of Solventum during the 4th quarter worth approximately $62,000. Beacon Pointe Advisors LLC raised its stake in shares of Solventum by 8.3% during the 4th quarter. Beacon Pointe Advisors LLC now owns 9,091 shares of the company's stock worth $601,000 after buying an additional 694 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Solventum by 21.5% during the 4th quarter. Northern Trust Corp now owns 1,749,301 shares of the company's stock worth $115,559,000 after buying an additional 309,077 shares in the last quarter.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on SOLV shares. KeyCorp started coverage on Solventum in a report on Friday, June 6th. They issued a "sector weight" rating on the stock. Argus upgraded Solventum from a "hold" rating to a "buy" rating and set a $90.00 price target on the stock in a report on Tuesday, July 1st. Wall Street Zen upgraded Solventum from a "buy" rating to a "strong-buy" rating in a report on Monday. Wells Fargo & Company increased their target price on Solventum from $75.00 to $79.00 and gave the stock an "equal weight" rating in a research report on Friday, August 8th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $94.00 target price (up from $87.00) on shares of Solventum in a research report on Friday, August 8th. Four analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $85.75.

Solventum Stock Down 2.3%

Shares of NYSE SOLV traded down $1.65 during mid-day trading on Tuesday, reaching $71.44. The company had a trading volume of 415,793 shares, compared to its average volume of 1,076,806. Solventum Corporation has a twelve month low of $60.70 and a twelve month high of $85.92. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. The stock has a market capitalization of $12.39 billion, a PE ratio of 33.10, a price-to-earnings-growth ratio of 1.77 and a beta of 0.53. The stock's 50 day moving average is $73.76 and its 200-day moving average is $72.80.

Solventum (NYSE:SOLV - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping the consensus estimate of $1.45 by $0.24. The firm had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business's quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the business posted $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, equities analysts anticipate that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.